128 related articles for article (PubMed ID: 1490360)
1. Inhibiting IL-6 in human multiple myeloma.
Klein B; Lu ZY; Gaillard JP; Harousseau JL; Bataille R
Curr Top Microbiol Immunol; 1992; 182():237-44. PubMed ID: 1490360
[No Abstract] [Full Text] [Related]
2. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments.
Lu ZY; Brailly H; Wijdenes J; Bataille R; Rossi JF; Klein B
Blood; 1995 Oct; 86(8):3123-31. PubMed ID: 7579407
[TBL] [Abstract][Full Text] [Related]
3. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma.
Bataille R; Barlogie B; Lu ZY; Rossi JF; Lavabre-Bertrand T; Beck T; Wijdenes J; Brochier J; Klein B
Blood; 1995 Jul; 86(2):685-91. PubMed ID: 7605999
[TBL] [Abstract][Full Text] [Related]
4. Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis.
Lu ZY; Brailly H; Rossi JF; Wijdenes J; Bataille R; Klein B
Cytokine; 1993 Nov; 5(6):578-82. PubMed ID: 8186369
[TBL] [Abstract][Full Text] [Related]
5. [Anti-cytokine therapy for intractable hematologic diseases using monoclonal antibodies].
Nishimoto N
Nihon Naika Gakkai Zasshi; 2004 Feb; 93(2):390-6. PubMed ID: 15007951
[No Abstract] [Full Text] [Related]
6. Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130.
Van Zaanen HC; Lokhorst HM; Aarden LA; Rensink HJ; Warnaar SO; Van Oers MH
Leuk Lymphoma; 1998 Nov; 31(5-6):551-8. PubMed ID: 9922045
[TBL] [Abstract][Full Text] [Related]
7. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.
Tai YT; Li X; Tong X; Santos D; Otsuki T; Catley L; Tournilhac O; Podar K; Hideshima T; Schlossman R; Richardson P; Munshi NC; Luqman M; Anderson KC
Cancer Res; 2005 Jul; 65(13):5898-906. PubMed ID: 15994968
[TBL] [Abstract][Full Text] [Related]
8. Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma.
Thomas X; Anglaret B; Magaud JP; Epstein J; Archimbaud E
Leuk Lymphoma; 1998 Dec; 32(1-2):107-19. PubMed ID: 10037006
[TBL] [Abstract][Full Text] [Related]
9. Clinical applications of IL6 inhibitors.
Klein B; Lu ZY; Bataille R
Res Immunol; 1992 Sep; 143(7):774-6. PubMed ID: 1439155
[No Abstract] [Full Text] [Related]
10. Pharmacokinetics of interleukin-6 during therapy with anti-interleukin-6 monoclonal antibodies: enhanced clearance of interleukin-6 by a combination of three anti-interleukin-6 antibodies.
Montero-Julian FA; Gautherot E; Wijdenes J; Klein B; Brailly H
J Interferon Res; 1994 Oct; 14(5):301-2. PubMed ID: 7861038
[No Abstract] [Full Text] [Related]
11. Cell surface expression and functional significance of adhesion molecules on human myeloma-derived cell lines.
Kim I; Uchiyama H; Chauhan D; Anderson KC
Br J Haematol; 1994 Jul; 87(3):483-93. PubMed ID: 7993788
[TBL] [Abstract][Full Text] [Related]
12. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.
van Zaanen HC; Koopmans RP; Aarden LA; Rensink HJ; Stouthard JM; Warnaar SO; Lokhorst HM; van Oers MH
J Clin Invest; 1996 Sep; 98(6):1441-8. PubMed ID: 8823310
[TBL] [Abstract][Full Text] [Related]
13. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6.
Legouffe E; Liautard J; Gaillard JP; Rossi JF; Wijdenes J; Bataille R; Klein B; Brochier J
Clin Exp Immunol; 1994 Nov; 98(2):323-9. PubMed ID: 7955540
[TBL] [Abstract][Full Text] [Related]
14. Transfusion-related inhibition of cytokines (TRICK). Experimental transfer of neutralizing autoantibodies to interleukin-6 by plasma transfusions.
Hansen MB; Galle P; Salomo M; Svenson M; Dickmeiss E; Gimsing P
Vox Sang; 2007 Apr; 92(3):213-23. PubMed ID: 17348870
[TBL] [Abstract][Full Text] [Related]
15. Homotypic cell aggregations of human myeloma cells with ICAM-1 and LFA-1 molecules.
Kawano MM; Huang N; Tanaka H; Ishikawa H; Sakai A; Tanabe O; Nobuyoshi M; Kuramoto A
Br J Haematol; 1991 Dec; 79(4):583-8. PubMed ID: 1685327
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of a novel anti-ICAM-1 immunotoxin on human myeloma cell lines.
Huang YW; Burrows FJ; Vitetta ES
Hybridoma; 1993 Dec; 12(6):661-75. PubMed ID: 7904588
[TBL] [Abstract][Full Text] [Related]
17. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.
Trikha M; Corringham R; Klein B; Rossi JF
Clin Cancer Res; 2003 Oct; 9(13):4653-65. PubMed ID: 14581334
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects.
Rossi JF; Fegueux N; Lu ZY; Legouffe E; Exbrayat C; Bozonnat MC; Navarro R; Lopez E; Quittet P; Daures JP; Rouillé V; Kanouni T; Widjenes J; Klein B
Bone Marrow Transplant; 2005 Nov; 36(9):771-9. PubMed ID: 16113665
[TBL] [Abstract][Full Text] [Related]
19. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
20. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo.
Suzuki H; Yasukawa K; Saito T; Goitsuka R; Hasegawa A; Ohsugi Y; Taga T; Kishimoto T
Eur J Immunol; 1992 Aug; 22(8):1989-93. PubMed ID: 1639101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
